{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T02:38:15Z","timestamp":1773887895901,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":30,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004704","name":"National Research Council of Thailand","doi-asserted-by":"publisher","award":["N42A670557"],"award-info":[{"award-number":["N42A670557"]}],"id":[{"id":"10.13039\/501100004704","id-type":"DOI","asserted-by":"publisher"}]},{"name":"IPS grants from the Faculty of Science, Mahidol University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-39102-5","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T09:36:43Z","timestamp":1771234603000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative evaluation of stability, efficacy, and sterility in five repackaged intravitreal anti-vascular endothelial growth factor medications"],"prefix":"10.1038","volume":"16","author":[{"given":"Panintorn","family":"Thunwiriya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanaporn","family":"Phetruen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phaewa","family":"Chaiwijit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaiyawat","family":"Tonawannakorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanokwan","family":"Dekham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nalumon","family":"Thadtapong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soraya","family":"Chaturongakul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Varodom","family":"Charoensawan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sittinan","family":"Chanarat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danaya","family":"Pakotiprapha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prut","family":"Hanutsaha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"key":"39102_CR1","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.3390\/ph16081140","volume":"16","author":"A Hang","year":"2023","unstructured":"Hang, A., Feldman, S., Amin, A. P., Ochoa, J. A. R. & Park, S. S. Intravitreal anti-vascular endothelial growth factor therapies for retinal disorders. Pharmaceuticals 16, 1140. https:\/\/doi.org\/10.3390\/ph16081140 (2023).","journal-title":"Pharmaceuticals"},{"key":"39102_CR2","doi-asserted-by":"publisher","unstructured":"Dorrell, M., Uusitalo-Jarvinen, H., Aguilar, E. & Friedlander, M. Ocular neovascularization: basic mechanisms and therapeutic advances. Surv. Ophthalmol. 52, S3-S19. (2007) https:\/\/doi.org\/10.1016\/j.survophthal.2006.10.017","DOI":"10.1016\/j.survophthal.2006.10.017"},{"key":"39102_CR3","doi-asserted-by":"publisher","first-page":"3453","DOI":"10.3390\/cells11213453","volume":"11","author":"H Heloter\u00e4","year":"2022","unstructured":"Heloter\u00e4, H. & Kaarniranta, K. A linkage between angiogenesis and inflammation in neovascular age-related macular degeneration. Cells 11, 3453. https:\/\/doi.org\/10.3390\/cells11213453 (2022).","journal-title":"Cells"},{"key":"39102_CR4","doi-asserted-by":"publisher","first-page":"101018","DOI":"10.1016\/j.preteyeres.2021.101018","volume":"88","author":"AS Tsai","year":"2022","unstructured":"Tsai, A. S. et al. Assessment and management of retinopathy of prematurity in the era of anti-vascular endothelial growth factor (VEGF). Prog. Retin. Eye Res. 88, 101018. https:\/\/doi.org\/10.1016\/j.preteyeres.2021.101018 (2022).","journal-title":"Prog. Retin. Eye Res."},{"key":"39102_CR5","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1080\/14712598.2022.2100694","volume":"22","author":"G Uludag","year":"2022","unstructured":"Uludag, G. et al. Efficacy and safety of intravitreal anti-VEGF therapy in diabetic retinopathy: What we have learned and what should we learn further? Expert Opin. Biol. Ther. 22, 1275\u20131291. https:\/\/doi.org\/10.1080\/14712598.2022.2100694 (2022).","journal-title":"Expert Opin. Biol. Ther."},{"key":"39102_CR6","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1159\/000508953","volume":"64","author":"M Imazeki","year":"2021","unstructured":"Imazeki, M. et al. Anti-VEGF therapy reduces inflammation in diabetic macular edema. Ophthalmic Res. 64, 43\u201349. https:\/\/doi.org\/10.1159\/000508953 (2021).","journal-title":"Ophthalmic Res."},{"key":"39102_CR7","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.3390\/pharmaceutics15051413","volume":"15","author":"L Ferro Desideri","year":"2023","unstructured":"Ferro Desideri, L., Traverso, C. E., Nicol\u00f2, M. & Munk, M. R. Faricimab for the treatment of diabetic macular edema and neovascular age-related macular degeneration. Pharmaceutics 15, 1413. https:\/\/doi.org\/10.3390\/pharmaceutics15051413 (2023).","journal-title":"Pharmaceutics"},{"key":"39102_CR8","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1056\/NEJMoa1414264","volume":"372","author":"G WellsJA","year":"2015","unstructured":"WellsJA, G. AyalaARDiabetic retinopathy clinical research network. Aflibercept, bevacizumab, or Ranibizumab for diabetic macular edema. N Engl. J. Med. 372, 1193\u20131203 (2015).","journal-title":"N Engl. J. Med."},{"key":"39102_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005139.pub3","author":"SD Solomon","year":"2014","unstructured":"Solomon, S. D., Lindsley, K., Vedula, S. S., Krzystolik, M. G. & Hawkins, B. S. Anti-vascular endothelial growth factor for neovascular age\u2010related macular degeneration. Cochrane Database Syst. Reviews. https:\/\/doi.org\/10.1002\/14651858.CD005139.pub3 (2014).","journal-title":"Cochrane Database Syst. Reviews"},{"key":"39102_CR10","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.ophtha.2011.12.005","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier, J. S. et al. Ranibizumab for macular edema due to retinal vein occlusions: Long-term follow-up in the HORIZON trial. Ophthalmology 119, 802\u2013809. https:\/\/doi.org\/10.1016\/j.ophtha.2011.12.005 (2012).","journal-title":"Ophthalmology"},{"key":"39102_CR11","unstructured":"Baker-Schena, L. & Expensive (eds) drugs. EyeNet Magazine, 39\u201344 (2017)."},{"key":"39102_CR12","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.ajo.2020.07.010","volume":"223","author":"GC Brown","year":"2021","unstructured":"Brown, G. C., Brown, M. M., Rapuano, S. B. & Boyer, D. A cost-benefit analysis of VEGF-inhibitor therapy for neovascular age-related macular degeneration in the united States. Am. J. Ophthalmol. 223, 405\u2013429. https:\/\/doi.org\/10.1016\/j.ajo.2020.07.010 (2021).","journal-title":"Am. J. Ophthalmol."},{"key":"39102_CR13","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s40123-023-00672-6","volume":"12","author":"OA Sam-Oyerinde","year":"2023","unstructured":"Sam-Oyerinde, O. A. & Patel, P. J. Real-world outcomes of anti-VEGF therapy in diabetic macular oedema: Barriers to treatment success and implications for low\/lower-middle-income countries. Ophthalmol. Therapy. 12, 809\u2013826. https:\/\/doi.org\/10.1007\/s40123-023-00672-6 (2023).","journal-title":"Ophthalmol. Therapy"},{"key":"39102_CR14","doi-asserted-by":"publisher","first-page":"2971","DOI":"10.1038\/s41598-022-06831-2","volume":"12","author":"J Juhong","year":"2022","unstructured":"Juhong, J. et al. The sterility, stability and efficacy of repackaged ziv-aflibercept for intravitreal administration. Sci. Rep. 12, 2971. https:\/\/doi.org\/10.1038\/s41598-022-06831-2 (2022).","journal-title":"Sci. Rep."},{"key":"39102_CR15","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.jcjo.2016.11.012","volume":"52","author":"S Cao","year":"2017","unstructured":"Cao, S., Cui, J., Matsubara, J. & Forooghian, F. Long-term in vitro functional stability of compounded Ranibizumab and Aflibercept. Can. J. Ophthalmol. 52, 273\u2013276. https:\/\/doi.org\/10.1016\/j.jcjo.2016.11.012 (2017).","journal-title":"Can. J. Ophthalmol."},{"key":"39102_CR16","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.oret.2018.08.002","volume":"3","author":"R Parikh","year":"2019","unstructured":"Parikh, R. et al. A multinational comparison of anti\u2013vascular endothelial growth factor use: The United States, the United Kingdom, and Asia-Pacific. Ophthalmol. Retina. 3, 16\u201326. https:\/\/doi.org\/10.1016\/j.oret.2018.08.002 (2019).","journal-title":"Ophthalmol. Retina"},{"key":"39102_CR17","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1080\/09273948.2020.1820530","volume":"30","author":"K Blom","year":"2022","unstructured":"Blom, K., Bragad\u00f3ttir, R., Sivertsen, M. S., Moe, M. C. & J\u00f8rstad, \u00d8. K. Does pharmaceutical compounding of vascular endothelial growth factor inhibitors for intravitreal use alter the risk of post-injection endophthalmitis? Ocul. Immunol. Inflamm. 30, 713\u2013716. https:\/\/doi.org\/10.1080\/09273948.2020.1820530 (2022).","journal-title":"Ocul. Immunol. Inflamm."},{"key":"39102_CR18","doi-asserted-by":"publisher","first-page":"9591","DOI":"10.3390\/ijms24119591","volume":"24","author":"T Tatsumi","year":"2023","unstructured":"Tatsumi, T. Current treatments for diabetic macular edema. Int. J. Mol. Sci. 24, 9591. https:\/\/doi.org\/10.3390\/ijms24119591 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"39102_CR19","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1089\/jop.2008.0043","volume":"25","author":"YH Chen","year":"2009","unstructured":"Chen, Y. H. et al. Evaluation of the sterility, stability, and efficacy of bevacizumab stored in multiple-dose vials for 6 months. J. Ocul. Pharmacol. Ther. 25, 65\u201370. https:\/\/doi.org\/10.1089\/jop.2008.0043 (2009).","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"39102_CR20","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1038\/eye.2015.28","volume":"29","author":"H Khalili","year":"2015","unstructured":"Khalili, H., Sharma, G., Froome, A., Khaw, P. T. & Brocchini, S. Storage stability of bevacizumab in polycarbonate and polypropylene syringes. Eye 29, 820\u2013827. https:\/\/doi.org\/10.1038\/eye.2015.28 (2015).","journal-title":"Eye"},{"key":"39102_CR21","doi-asserted-by":"publisher","first-page":"882013","DOI":"10.3389\/fopht.2022.882013","volume":"2","author":"TT Gj\u00f8lberg","year":"2022","unstructured":"Gj\u00f8lberg, T. T. et al. A silicone oil-free syringe tailored for intravitreal injection of biologics. Front. Ophthalmol. 2, 882013. https:\/\/doi.org\/10.3389\/fopht.2022.882013 (2022).","journal-title":"Front. Ophthalmol."},{"key":"39102_CR22","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1038\/s41598-018-20525-8","volume":"8","author":"MS Sivertsen","year":"2018","unstructured":"Sivertsen, M. S. et al. Pharmaceutical compounding of Aflibercept in prefilled syringes does not affect structural integrity, stability or VEGF and Fc binding properties. Sci. Rep. 8, 2101. https:\/\/doi.org\/10.1038\/s41598-018-20525-8 (2018).","journal-title":"Sci. Rep."},{"key":"39102_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40942-018-0143-x","volume":"4","author":"L de Farah","year":"2018","unstructured":"de Farah, L. Evaluation of Aflibercept and ziv-aflibercept binding affinity to vascular endothelial growth factor, stability and sterility after compounding. Int. J. Retina Vitreous. 4, 1\u20137. https:\/\/doi.org\/10.1186\/s40942-018-0143-x (2018).","journal-title":"Int. J. Retina Vitreous"},{"key":"39102_CR24","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s40942-023-00507-3","volume":"9","author":"\u00d8K J\u00f8rstad","year":"2023","unstructured":"J\u00f8rstad, \u00d8. K. et al. Pharmaceutical compounding and storage of faricimab in a syringe for intravitreal injection do not impair stability and bi-specific binding properties. Int. J. Retina Vitreous. 9, 65. https:\/\/doi.org\/10.1186\/s40942-023-00507-3 (2023).","journal-title":"Int. J. Retina Vitreous"},{"key":"39102_CR25","doi-asserted-by":"publisher","unstructured":"Taschauer, A. et al. Faricimab maintains substance integrity and sterility after compounding and storage in two different polypropylene syringe types. Eye  https:\/\/doi.org\/10.1038\/s41433-024-03511-5 (2024).","DOI":"10.1038\/s41433-024-03511-5"},{"key":"39102_CR26","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1128\/am.11.4.305-309.1963","volume":"11","author":"A Gaudy Jr","year":"1963","unstructured":"Gaudy, A. Jr, Abu-Niaaj, F. & Gaudy, E. Statistical study of the spot-plate technique for viable-cell counts. Appl. Microbiol. 11, 305\u2013309. https:\/\/doi.org\/10.1128\/am.11.4.305-309.1963 (1963).","journal-title":"Appl. Microbiol."},{"key":"39102_CR27","unstructured":"Convention, U. S. P. USP General Chapter\u2009<\u200971>, Sterility tests, (2016). https:\/\/www.usp.org\/sites\/default\/files\/usp\/document\/harmonization\/gen-method\/q11_pf_ira_34_6_2008.pdf"},{"key":"39102_CR28","unstructured":"Convention, U. S. P. USP General Chapter\u2009<\u200962>, Microbiological examination of nonsterile products: tests for specified microorganisms (2016). https:\/\/www.usp.org\/sites\/default\/files\/usp\/document\/harmonization\/gen-method\/q05b_pf_ira_34_6_2008.pdf"},{"key":"39102_CR29","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1001\/jamaophthalmol.2014.3591","volume":"133","author":"NA Yannuzzi","year":"2015","unstructured":"Yannuzzi, N. A. et al. Evaluation of compounded bevacizumab prepared for intravitreal injection. JAMA Ophthalmol. 133, 32\u201339. https:\/\/doi.org\/10.1001\/jamaophthalmol.2014.3591 (2015).","journal-title":"JAMA Ophthalmol."},{"key":"39102_CR30","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1345\/aph.1L270","volume":"42","author":"K \u00d6rnek","year":"2008","unstructured":"\u00d6rnek, K., Karahan, Z. C., Ergin, A., Tekeli, A. & Tekeli, O. Bevacizumab sterility in multiple doses from a single-use vial. Ann. Pharmacother. 42, 1425\u20131428. https:\/\/doi.org\/10.1345\/aph.1L270 (2008).","journal-title":"Ann. Pharmacother."},{"key":"39102_CR31","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.ejpb.2016.09.003","volume":"108","author":"M Moreno","year":"2016","unstructured":"Moreno, M. et al. Study of stability and biophysical characterization of Ranibizumab and Aflibercept. Eur. J. Pharm. Biopharm. 108, 156\u2013167. https:\/\/doi.org\/10.1016\/j.ejpb.2016.09.003 (2016).","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"39102_CR32","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1038\/eye.2013.139","volume":"27","author":"J Palmer","year":"2013","unstructured":"Palmer, J., Amoaku, W. & Kamali, F. Quality of bevacizumab compounded for intravitreal administration. Eye 27, 1090\u20131097. https:\/\/doi.org\/10.1038\/eye.2013.139 (2013).","journal-title":"Eye"},{"key":"39102_CR33","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1111\/ceo.12489","volume":"43","author":"T Das","year":"2015","unstructured":"Das, T. et al. Safety, sterility and stability of direct-from\u2010vial multiple dosing intravitreal injection of bevacizumab. Clin. Exp. Ophthalmol. 43, 466\u2013473. https:\/\/doi.org\/10.1111\/ceo.12489 (2015).","journal-title":"Clin. Exp. Ophthalmol."},{"key":"39102_CR34","unstructured":"Murray, P. R., Baron, E. J., Jorgensen, J. H. & Landry, M. L. Manual of clinical microbiology (Amer society for microbiology) (2007)."},{"key":"39102_CR35","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.xphs.2020.09.043","volume":"110","author":"DP Chang","year":"2021","unstructured":"Chang, D. P. et al. Long-term stability of anti-vascular endothelial growth factor (a-VEGF) biologics under physiologically relevant conditions and its impact on the development of long-acting delivery systems. J. Pharm. Sci. 110, 860\u2013870 (2021).","journal-title":"J. Pharm. Sci."},{"key":"39102_CR36","unstructured":"Convention, U. S. P. USP General Chapter\u2009<\u2009795>, Pharmaceutical compounding \u2013 nonsterile preparations, (2024). https:\/\/www.usp.org\/compounding\/general-chapter-795"},{"key":"39102_CR37","unstructured":"Convention, U. S. P. USP General Chapter\u2009<\u2009797>, Pharmaceutical compounding \u2013 sterile preparations, (2024). https:\/\/www.usp.org\/compounding\/general-chapter-797"},{"key":"39102_CR38","doi-asserted-by":"publisher","unstructured":"Gasteiger, E. et al. Protein identification and analysis tools on the expasy server. Proteom. Protocols Handb. https:\/\/doi.org\/10.1385\/1-59259-890 (2005).","DOI":"10.1385\/1-59259-890"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-39102-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-39102-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-39102-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T22:02:04Z","timestamp":1773871324000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-39102-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,16]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["39102"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-39102-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,16]]},"assertion":[{"value":"24 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"During the preparation of this work, the authors used ChatGPT and Google Gemini, exclusively to improve readability and for grammar check. After using these tools, the authors reviewed and edited the content as needed and took full responsibility for the content of the publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of generative AI and AI-assisted technologies in the writing process"}}],"article-number":"9306"}}